Pallas Capital Advisors LLC Takes $298,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

Pallas Capital Advisors LLC bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 1,519 shares of the medical research company's stock, valued at approximately $298,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. FMR LLC boosted its holdings in IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after purchasing an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of IQVIA in the 3rd quarter worth approximately $147,683,000. JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Nordea Investment Management AB boosted its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after buying an additional 452,029 shares in the last quarter. Finally, 1832 Asset Management L.P. increased its holdings in IQVIA by 472.3% in the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company's stock valued at $96,487,000 after buying an additional 376,595 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a research note on Wednesday, December 11th. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a report on Thursday, November 28th. The Goldman Sachs Group decreased their price target on IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Morgan Stanley dropped their price objective on IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Finally, Bank of America reduced their target price on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research note on Friday, December 13th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and an average price target of $255.82.

IQVIA Trading Up 0.8 %

Shares of IQVIA stock traded up $1.61 during trading on Thursday, reaching $197.71. 1,208,107 shares of the company were exchanged, compared to its average volume of 1,297,661. The business has a 50-day moving average price of $200.93 and a 200-day moving average price of $221.44. The firm has a market capitalization of $35.89 billion, a price-to-earnings ratio of 25.95, a P/E/G ratio of 2.09 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.